Sanj K. Patel; CEO & Chairman of the Board; Kiniksa Pharmaceuticals Ltd
Good day. And thank you for standing by. Welcome to the Kiniksa Pharmaceuticals third quarter, 2024 earnings conference call. At this time all participants are in a listen-only mode. Please be advised that today's conference is being recorded after the speaker's presentation. There will be a question and answer session to ask a question. Please press star 11 on your telephone and wait for your name to be announced. To withdraw your question. Please press star 11 again. I would now like to hand the conference over to your speaker today, Jonathan Kirschenbaum Investor Relations.
Thank you operator. Good morning, everyone and thank you for joining Kiniksa call to discuss our third quarter, 2024 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the investors section.
As for the agenda, our Chief Executive Officer Sanj K Patel will start with an introduction, Ross Moat, our Chief Commercial Officer will provide an update on our commercial execution. Then Mark Ragosa, our Chief Financial Officer will review our third quarter 2024 financial results. And finally Sanj will return for closing remarks and to kick off the Q&A session for which John Paolini, our Chief Medical Officer and Eben Tessari, our Chief Operating Officer will also be on the line. Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. Our review of such statements and risk factors can be found on this slide as well as under the caption. Risk factors contained in our SEC filings. These statements speak only as of the date of this presentation and we undertake no obligation to update such statements except as required by law. With that, I'll turn it over to Sanjh.
Thanks Jonathan and good morning everyone.
Kiniksa is a well capitalized growth orientated company that's well positioned for near and long term success. In the third quarter we continued to drive strong commercial performance with Arcalyst including increased prescriber adoption and repeat prescriber growth.
Patients and physicians continue to report high levels of satisfaction with Arcalyst and our market building activities are positioning us to provide that positive experience to more patients in need.
Importantly, as we head into the end of the year, we are increasing our full year Arcalyst net sales guidance to between $410million to $420 million. From the previous guidance range of $405million to $415 million. In our pipeline we continue to enroll and dose patients in the Abiprubat phase two B study in Sjogren's disease.
Clinical development of a group art is fully funded in our current operating plan.
Importantly, our robust financial position and expectation of positive annual cash flow support growth investments across our business including commercial initiatives, portfolio enhancement and value adding business development, which remains a key part of our strategy.
Commercially, the third quarter saw a continuation of our sequential growth.
We saw a 73% year over year growth with Arcalyst. Ultimately delivering $112.2million of net product revenue for the quarter.
The continued growth over the past 3.5 years is a testament to our team and our commercial organization.
We are well positioned to maximize the potential of Arcalyst, the only FDA approved therapy for recurrent pericarditis.
The collaboration has been profitable since the fourth quarter of 2021 enabling further investments in commercial growth oriented initiatives across multiple channels including our salesforce, patient and physician disease education and brand awareness.
In the third quarter, the impact of these investments contributed to increases in key commercial drivers. These are total prescribers since launch increased from approximately 2,300 in Q2 to approximately 2,550 in Q3.
Importantly, we also saw an increase in the repeat prescriber rate with approximately 25% of prescribers. Since launch writing multiple prescriptions.
Additionally, prescribers appear to appreciate that recurrent pericarditis is a debilitating chronic disease that should be treated to the duration of the underlying autoinflammation.
This is reflected by the increase in the total average duration of therapy to 27 months as of the end of Q3. Continued strength across our underlying fundamentals also supported the Q3 commercial performance.
We continue to observe high patient and physician satisfaction with patient compliance remaining above 85% and greater than 90% payer approval of completed cases.
With that, I'll turn it over to Ross to provide an overview of how we plan to provide additional growth with Arcalyst. Ross.
Ross Moat
Thank you Sanj.
As Sanj noted in Q3, Kiniksa's commercial team activated more than 250 new Arcalyst prescribers compared to the previous quarter, which is an increase of more than 1,000 additional new prescribers compared to Q3 of last year. This brings the total prescriber base to approximately 2,550 since launch and demonstrates accelerated growth in the breadth of prescribing with archivists, which is a key part of our dual commercial strategy.
Additionally, in Q3, we also drove an acceleration in the depth of prescribing with around 640 health care professionals who have now prescribed Arcalyst for two or more patients since launch represented around 25% of the ever growing total prescriber base.
This growth reflects that once a physician is activated, they generally have a positive prescribing experience due to the very high payer approval rate and the significant clinical efficacy of Arcalyst, which increases the desire to identify and treat additional patients.
The growth in both total and repeat Arcalyst prescribers speaks to the growing awareness of recurrent pericarditis and the understanding of Arcalyst as the only FDA approved treatments for the disease.
On the next slide, I'd like to highlight how we're continuing to change the treatment paradigm and how physicians are changing their future prescribing intentions towards Arcalyst.
Among surveyed cardiologists and rheumatologists, we have seen a substantial increase in the proportion of physicians who will continue who will consider prescribing Arcalyst with each additional recurrence. Importantly, on the right side of the slide, we're seeing that physicians are acting upon this intent. Since the launch of oculists in recurrent pericarditis. Just over three years ago, we have been highly targeted in our field sales efforts against the 14,000 patients on two or more recurrences while ensuring physicians also understand the broad label and ability to prescribe earlier in the disease.
In line with our promotional efforts, we are seeing around 85% of all articles prescribing is for the two plus recurrent population and around 15% of all scripts being written for patients on their first recurrence.
Ultimately, this earlier utilization speaks not only to the stellar effectiveness of ar but also to the effectiveness of our brand and disease awareness efforts aimed at educating both patients and physicians around the chronic nature of this disease and the opportunity to prevent future flares.
These data provide further evidence that the promotion and availability of Arcalyst have driven a change in the treatment landscape away from nonspecific drug agents and towards Arcalyst as a targeted treatment directly addressing the underlying mechanism of recurrent pericarditis.
Continuing our focus on accelerating disease awareness and improving the patient journey to diagnosis. I'd like to highlight two exciting initiatives. Firstly, earlier this month, we announced the launch of life disrupted a recurrent pericarditis educational campaign with National Hockey League Hall of Famer, Henrik Lundquist. And just yesterday, we announced that Grammy Award winning singer songwriter Carly Pearce has also joined the campaign.
Disease Awareness is a key component in our commercialization strategy for Arcalyst.
One of the key drivers behind our life disrupted campaign is that despite the profound impact the disease has on patients, 96% of patients report that they were initially incorrectly diagnosed with other conditions.
On average patients reported 2.7 misdiagnoses prior to receiving a diagnosis of recurrent pericarditis. This results in a delayed diagnosis and we believe we have an opportunity to increase education and improve the patient journey and optimize patient care.
In addition to life disrupted, we're also sponsoring the American Heart Association's addressing recurrent pericarditis initiative. This initiative seeks to improve the quality of care for recurrent pericarditis patients by identifying and disseminating best practices for the diagnosis and treatment of the disease. Specifically through our sponsorship, 15 centers of excellence have been identified across the US and are working together to improve referral pathways and develop solutions that can be shared with other pericardial disease clinics across the country.
Based on our market experience, the streamlining of referral pathways could reduce the barriers to care and ultimately improve outcomes for patients. In a Harris poll, 71% of recurrent pericarditis patients stated they would be highly likely to seek care at a recurrent pericarditis focus clinic, If one were available in that area. we're looking to address that need and aim to continue advancing the support for patients suffering from this debilitating disease.
In Q3, the kita team continued to drive sequential growth in Arcalyst revenue. As a result, we've increased our full year 2024 Arcalyst net sales guidance to $410million to $420 million from $405milion to $450 million with that. And I'll turn it over to mark to discuss our third quarter financial results mark.
Mark Ragosa
Thanks Ross. Our detailed third quarter, 2024 financial results can be found in the press release we issued earlier today.
There are several items on the slide that I'd like to call your attention to this morning.
First total revenue in the third quarter of 2024 was driven entirely by acla net product revenue which grew 73% year over year to 112.2 million.
Second Arcalyst collaboration operating profit in the third quarter grew 68% year over year to $58.2 million and largely drove total collaboration expenses of $29.3 million.
Third on a year over year basis. In the third quarter, operating expense growth was due to cost of goods sold driven by Arcalyst revenue growth as well as expenses related to the ongoing Arcalyst tech transfer collaboration, expenses driven by Arcalyst collaboration, operating profit growth and R&D and SG&A driven largely by personnel costs, manufacturing of clinical supply and Arcalyst commercialization.
Fourth net loss in the third quarter of 2024 was $12.7 million compared to a net loss of $13.9 million in the third quarter of 2023.
Lastly net cash flow in the third quarter was $5 million. Bringing end of period cash balance to $223.8 million.
We continue to expect our cash reserves as well as strong commercial execution and financial discipline to fund our current operating plan and we expect to remain cash flow positive on an annual basis.
With that, I'll turn the call back to Sanj for closing remarks.
Sanj K. Patel
Thanks Mark. We are as ever dedicated to helping as many patients as possible with our Arcalyst and advancing the development of our clinical portfolio to help bring additional therapies to patients that are suffering from debilitating diseases.
Both of these important goals are integral to our ongoing efforts to create sustainable value and grow connects into a generational company.
With that. I'll now turn the call back to the operator for questions.
Thank you.
Operator
(Operator Instruction)
Our first question comes from Roger Song with Jefferies. He may proceed.
Roger Song
Great. Congrats for the quarter and thank you for taking our question. Maybe the first one is regarding the the penetration of the market share in the first recurrent patient. That's interesting. You have 15% of your prescription is coming from the first recurrence which is in the label. Just curious how you can keep driving the penetration into that population. I know your initial target is in the multiple recurrence. Thank you.
Ross Moat
Thanks Roger. Yeah, this is Ross. So thank you very much for the question. So you're absolutely right that our primary focus is the 14,000 patient population. They're the patients that are suffering from two or more recurrences that's been our key target ever since since we launched more than three years ago. The reason for that is that they're the patients that are ultimately suffering the highest burden of the disease. And they're the patients that are most resembling the patients that were studied in the Rhapsody data sets as well. At the end of Q2, we announced that we'd reached around 11% penetration into that target population. So I think that speaks to the huge opportunity that we still have ahead within the two plus recurrence. But having said that as we highlighted in the prepared remarks, it's also encouraging that healthcare professionals are understanding how broad the label is for recurrent pericarditis and some of them are seeking to use it on the first occurrence. So we're very pleased with that. We think it speaks to just the efficacy of Arcalyst and ultimately the desire to help patients by reducing the risk of future flares, which is one of the key components of a treatment. So we, we're pleased with that. I think one thing to note is that on the duration, in terms of the natural history, the disease, the median duration of those patients that are on their first recurrence is often shorter. It's around six months for the patients on the first recurrence compared to a median of around three years for those patients that are on two or more recurrences. Which is another reason why, you know, a key target audiences is those that are on their 2 plus recurrences. But we're very pleased to have announced that additional insight today into how physicians are treating earlier in the disease and you know, see an Arcalyst being used to really prevent, prevent future flares within that. So we continue to focus on disease education and, and you know, reaching further into the penetration of you know, all of the, the recurrence groups within our label. But as we've mentioned, it's really the 14,000 patients that are the key target and I guess seeing the additional 26,000 population that are on their first recurrence as a to that case.
Roger Song
Got it. Yeah, thank you for the comment. I think that's the upside coming from this even larger population there. Okay. And then my follow up question is related to the the QonQ growth rate. I understand the year on year growth rates continue to be very strong. And then how should we think about the growth rate from from here in terms of the fourth quarter and the next year? Are we reaching the steady state for the growth from here? Thank you.
Ross Moat
Yeah, thanks Roger. I'm not sure whether we're reaching a, you know, a steady state in the growth rate or not, we'll see as things progress, but obviously we're, we're intent on continued growth and we think we've got a very large opportunity ahead knowing where we are with the current penetration and the trajectory that we've been on launched to date. I guess we've always said that it's a, you know, this is a build and a steady growth as we identify patients. But we're pleased to have landed at $112.2 million in Q3, which is around 8.5% growth versus Q2, which was a quite a large Q2 that we announced. So we were pleased to be able to increase the guidance due to that, that rate of growth now up to $410million to $420 million.
Roger Song
Got it. Yes, your Q2 is a big number. Thank you. That's all from us. Congrats again.
Ross Moat
Thanks Roger.
Operator
Thank you.
Our next question comes from Liisa Bayko with Evercore ISI. You may proceed.
Liisa Bayko
Hi there. Thanks for taking the question. Just a couple from us. First, can you I don't know if you said this but remind us what gross to nets were for the quarter?
Mark Ragosa
Yeah, sure, Lisa. So year-to-date gross net through the third quarter was was 9.8% which is down from 10.8% in the, in the second quarter of this year.
Liisa Bayko
Okay, great. And then just thinking about the flow of patients and, and you have an incredible amount of you know, kind of prescribers, repeat prescribers and a really nice long kind of mean duration of of 27 months. How many patients if you could qualify or what percentage you know, started and maybe discontinued or sort of did stop at some point. I'm just trying to get a sense of, you know, how many people have been on therapy thus far. Thanks.
Ross Moat
Yeah, thanks Liisa. So we just haven't shared some of those those kind of more granular insights that we do have a slide on our our corporate deck, which speaks to the duration, both in terms of the total duration, which is now up to 27 months from 26 months at the last earnings call, as well as looking at the drop off of those patients that are on their first treatment period. And from that, you can see that even out at this time since launch and a half years ago now, and we've still got, you know, around 20% or so of the patients who started in the initial launch quarter and are still on their initial treatment period. So they, you know, they've obviously not stopped therapy at any point throughout that time period. So clearly, we have patients that, you know, start therapy and will remain on therapy for a long period of time as the natural history showed us as well. But then also, you know, obviously we do have patients that drop off much sooner than that. We still see that there's around 45% restart rate in totality. So all those patients who stop, regardless of which time point they stop therapy at about 45% of them restart therapy. Still the vast majority of those when they do restart it within an eight week time period, showing that if there is underlying auto inflammation, still ongoing within the patient. You know, symptomology can come back pretty quickly. As after this washes off and the need to restart treatment, which is a generally a very easy process for patients. But it just again, speaks to the need that this is really a, a chronic disease as Sanj was saying in the remarks and we really do need to treat to the underlying duration of the disease. But the totality now of the treatment duration is around 27 months, up to the most recent information.
Liisa Bayko
Okay. And it seems like it's, it's helpful to get more feet on the ground on more sales force. You're obviously being able to, you know, find more patients and there's still so many more out there. Do you think that you're right size? Do you think we might see additional growth in the sales force over time? Just curious how you're thinking about that longer term? And that's my last question. Thanks.
Sanj K. Patel
Yeah thanks Liisa, This is Sanj. I mean, obviously we've thought about, you know, you've obviously tracked that we from the initial launch, we've actually expanded that from the initial 29 to around 50 then most recent reported around 85-90. And that's just based on a lot of analytics. So we'll continue to look at it and apply what we think is right. You know, we do this in a very data driven manner. It's important to get the balance just right. So we'll continue to look at it and we'll do what's needed.
Liisa Bayko
Great.
Operator
Thank you.
Our next question comes from Paul Choi with Goldman Sachs. You may proceed.
Paul Choi
Hi. Thanks, good morning and thanks for taking our questions. My first one is just with regard to the, the patients who are the 15% of patients who are treated as, as their first recurrence. Can you maybe just comment on sort of guideline awareness of Arcalyst as a first treatment option for their first recurrence and just kind of where the physician community is and sort of understanding that.
And my second question is, thanks for the Abiprubart update. Can you maybe comment if you have sort of any visibility on timing for enrollment here? And when, when the last patient you think might be enrolled, at least based on what what you can see in the patient recruiting now. Thanks for taking our questions.
Ross Moat
Sure. Thank you, Paul. And I appreciate the questions. Maybe I'll just answer quickly the Abiprubart question first and then go back to the question about first line therapy. So with regard to the Abiprubart phase two B study and children's disease, Yes, we're very excited about that study, which has, which is now enrolling and dosing patients. At this point in time, we have not given any specific guidance about enrollment timelines because of the fact that the study is, is just starting. But by way of a reminder, this is a 24 week study to the primary efficacy endpoint. So six months of treatment followed by an additional six months long term extension. And what's unique about this study is that it is the only study in the space testing monthly subcutaneous dosing of CD 40 antagonist. So that's the Abiprubart study. Now, back to your your first question about guideline awareness and treatment of of patients as you know, is as early as their first recurrence. So as you'll remember, there, the last treatment guidelines that were written were actually from Europe that were written in 2015. So of course, that predated all of the work in in interleukin one and the awareness of interleukin one alpha and beta is key driver of of recurrent per card.
And so since then, of course, with all of the work that we've done with Arcalyst and Rhapsody and the ultimate approval of Rilonacept Abiprubart is the first and only treatment, you know, treatment for recurrent pericarditis and also reduction in risk. What that has done is it has left, as you mentioned, you know, a broad label. So what that means is that patients can be treated as soon as there is a diagnosis. So how does that then translate into how physicians have been treating patients? So, in the absence of guidelines and we hear that European guidelines may be updated in the next few years. But in the meantime, what has happened is thought leadership has been writing in the literature more about an evidence, this evidence based approach of treating patients with Ian pathway inhibition and specifically rhapsody tested not only basically two paradigms or two different ways of steroids bearing paradigm. The first one of course is that for patients who are on steroids to get them off of steroids. But then more importantly for patients who are failing nsaids and colchicine. So a strategy of inflamax inhibition to get them onto one pathway inhibition right away. And so that often translates if you will into many patients who are at their first recurrence who are breaking through nsaids and colchicine with aggressive disease. And so clinicians are looking to that. In terms of how that's translated into the real world, our data from the Residentid Registry, you know, shows that since the time of Arcalyst launch, you know, a real rise in second line use of Arcalyst as second line therapy such that two thirds of prescriptions of patients that were treated with, you know, with who are failing NSAIDS and co we actually managed with IO one pathway inhibition. So I think that's where you're seeing this evidence based approach of translating the label into practice.
Paul Choi
Okay, great. Thank you.
Operator
Thank you.
Our next question comes from Eva Forteo Verdejo with Wells Fargo. You may proceed.
Eva Forteo Verdejo
Good morning. Congrats on the quarter and thanks for taking our question. A couple from us, the first one you mentioned mean duration of 27 months. Should we expect some differences here on mean duration for patients on first recurrence versus 2nd and 3rd recurrence?
And the second question is what's driving the current increase in patient? As is it mostly coming from these patients on first recurrence or are you seeing similar growth on this like three buckets of like first versus 2nd and 3rd? Thanks.
Ross Moat
Thanks Eva, so this is Ross. Maybe I'll take the your, your last question first and then I'll hand over to John to, to talk through the first part of the question regarding patient ads, I mean, we're seeing patients added both from new prescribers that are coming on board. We've seen quite a healthy clip of increase of new prescribers quarter on quarter. So most recently, you know, around 250 additional new prescribers, we're also seeing the repeat prescriber basis increase as well. So as a result of that, we're certainly driving, you know, more total patients that are on therapy. So by the time you account for those patients who have stopped therapy for about a quarter after having come to the natural cessation of, of disease and, and drug. Obviously we're putting on far more new patients than we are losing at the other end each, each quarter. And then the increased total duration of therapy is also helping with that as well. So we're seeing, you know, we're seeing a good kind of increase there which we're happy to, to report.
So maybe John, do you want to make?
John Paolini
Yeah. No, you, you've asked a very interesting question about the the epidemiology of recurrent pericarditis.
So you know what we know from our data is that for patients who have two or more recurrences that the median disease duration is three years with a third of patients still suffering in five years and a quarter of patients still suffering at eight years. And so you know that as as you might imagine is a key driver of a strategy treatment throughout the duration of the disease. And that's been shown repeatedly with clinical trials data as well that premature cessation of therapy, whether at three months, 18 months or even 28 months results at a very high rate of recurrence and need for advanced targeted therapy. Now, with regard to the earlier recurrence patients, yes, the epidemiology there is slightly different that it's taken in the aggregate the median duration of disease for patients with one recurrence is six months. But it's important to note that that includes all of those patients that will a number of patients who will run to the course of their disease relatively quickly within the 1st year. But it also includes those patients who will in fact go on to have long term disease. And those patients tend to have a more aggressive presentation, you know, at the time of their first recurrence. And that's why again, going back to that literature that I cited earlier, the second line use of Iowa pathway inhibition in that patient population who are failing nsaids and colchicine usually reflect a treatment strategy on the part of the physician that they believe that nsaids and colchicine will be inadequate to manage those patients. And so those tend to be the longer duration patients.
Ross Moat
Yeah, and maybe just to add on to the end of that John, thank you. Is that that ultimately the key driver of the new patient adds is really those patients that are on two or more recurrences. While it's pleasing to hear and understand that there are physicians utilizing earlier on in the disease on their first recurrence, you know, the more than 85 well around 85% on the two or plus recurrence. And then if you take into account the duration of the disease as John has spoken to, you can see that it's a two plus recurrence group that are really the main driver of the disease. If you look back at the first recurrence, you know, there's around 33% of physicians now that we have surveyed that inform us that it was their intention to consider ARS on the first recurrence. So it's good that arch is being considered earlier on in the disease. That's not to say, obviously, ALL 33% will go on and prescribe within that first recurrence. But at least it's an indication that the awareness of Arcalyst is growing physicians are considering using it early. And also now that we see around 15% of the Arcalyst prescriptions or enrollments that are within the first recurrence. So it's pleasing data, but ultimately, it's the two plus recurrence group that's really driving the business here.
Operator
Thank you.
Our next question comes from David Nierengarten with Wedbush Securities. You may proceed.
David Nierengarten
Thanks for taking the question most have been asked, but I did have a follow up on the, you know, the first recurrence and not to be labor the point, but maybe it's early. But are there any trends towards the doctors who are prescribed or more repeat prescribers prescribing earlier or is it scattered across the board amongst doctors? Thanks.
Ross Moat
Yeah, thanks, David. It's a great question. I think we see it really scattered across the board and I don't see any particular correlations of notes yet, which is why we haven't really shared anything around that topic. You know, we, we do obviously have a clear understanding that the patients are very widely dispersed across the US. And there is a need for patients to get diagnosed earlier in the disease rather than suffering from all the misdiagnoses that we see. So that often elongates the journey through to diagnosis. And obviously, there's a knock on effect of that through to treatment as well. So we think that's, you know, a key component for us to look at and consider how we can partner with people to try to get, you know, diagnosis. Earlier, as we mentioned, the initiative that we sponsored through the American Heart Association to focus on, you know, 15 Centers of Excellence. Now really focusing on the pericardial diseases of which current pericarditis being one of them is a an interesting initiative that really aims to shorten that treatment pathway. And the the pathway through to accurate diagnosis and how the learnings from those expert centers can really be shared throughout the rest of the the community. So we think that's an important initiative that also kind of goes into a part of our strategy around increasing the awareness and just helping patients to get an earlier diagnosis.
David Nierengarten
Thank You.
Operator
Thank you. And as a reminder to ask a question, please press star 11 on your telephone. And our next question comes from Anupam Rama with JP Morgan. You may proceed.
Anupam Rama
Hey guys, thanks so much for taking the question and congrats on the quarter. Last year you guys pre announced and gave forward your guidance at a small health care conference in January in San Francisco. Just wondering if that's still the plan moving forward. Thanks so much.
Sanj K. Patel
You're assuming we're going to the small healthcare conference in January. Now, thanks a, you know, at this point, we're not quite sure what we're going to do, but certainly that was the case last year. You know, as always, we look at it very carefully and we will do it when we do it. But at this point, we've not made any final decisions, but thank you for the reminder.
Anupam Rama
Thanks for taking your question.
Sanj K. Patel
Thanks.
Operator
Thank you. I would now like to turn the call back over to Sanj Patel for any closing remarks.
Sanj K. Patel
No, thank you everybody for for being on the call today. Thanks for all the questions and joining us. We look very much forward to the remainder of the year and then obviously providing additional updates as just as I just said seminar and then hopefully in the near future. So thank you very much.
Operator
Thank you. This concludes the conference. Thank you for your participation. You may now disconnect.